Omnicell Unveils Innovative IVX Station Robotic Compounding Technology in Winter 2022 Release

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced the launch of IVX Station.

Omnicell advises this innovative solution is designed to scale the benefits of leveraging IV robotic technology, making it accessible to the mainstream market.

Omnicell’s Winter 2022 Release introduces new technology and enhancements to existing solutions that are expected to add value for customers. The new solutions and capabilities are intended to automate workflows, optimize operations and, most importantly, help improve patient care in an increasingly complex regulatory environment.

IVX Station: Reimagining Technology for Maximum Throughput and Reliability

According to the Institute for Safe Medication Practices (ISMP),¹ not only are manual sterile compounding practices labor intensive, but they also can create patient safety risks. IV robotics have demonstrated proven benefits for safe, efficient sterile compounding for over 15 years, yet adoption of the technology has been limited due to throughput and reliability concerns.^2,3

Omnicell’s completely reimagined, fully automated IV compounding robot is designed to deliver the patient safety, accuracy, cost savings, supply chain control, and compliance benefits of its predecessors while addressing industry issues with throughput and reliability. IVX Station supports three times the throughput speed of current IV robotic technology,⁴ features a design focused on high reliability with a precision-machined super structure to eliminate the number one cause of downtime – re-calibration, and maintains the approximate footprint of a four-foot hood.

IVX Station is available through Omnicell’s IV Compounding Service, which combines the technology with expertly trained pharmacy technicians and services in an effort to ensure value realization. This “as-a-Service” approach should help to reduce reliance on outsourced sterile compounding, while allowing health systems to reduce drug waste in the operating room.

“Nearly a decade ago, University of Rochester Medical Center began a journey toward a fully autonomous approach to medication management as an early adopter of IV robotics technology,” said David Webster, RPh, MSBA, director of acute care pharmacy operations at University of Rochester Medical Center. “Improving quality and safety in compounding operations is a long-term strategic investment we made to enhance patient care and elevate the role of the pharmacy. We believe Omnicell’s IVX Station will be a catalyst for driving operational and patient safety priorities, ultimately helping us advance technology-driven pharmacy operations.”

Strengthening the Intelligent Infrastructure for Medication Management

With the Winter 2022 Release, Omnicell has strengthened its portfolio of intelligent infrastructure solutions for medication management with the following enhancements:

• Omnicell One™ scorecard and benchmarking capabilities: New capabilities within the cloud-based, technology-enabled service consolidate pharmacy supply chain data from across a provider’s ecosystem. Medication location, quantity, and usage information can now be tracked to reduce the likelihood of stockouts that can negatively impact patient care. Scorecards designed to track Spend, Savings, and Pharmacy Performance should enable pharmacy leaders to streamline resource planning, enhancing operational efficiency and value.Additional functionality in Omnicell One allows health systems to benchmark their organization with ISMP best practices for overrides as compared to similar health systems. This feature helps identify factors leading to over-reliance on overrides.
• New Refrigerated Carousel: Refrigerated medications comprise 20 percent of overall hospital drug spend,⁵ making it crucial to have supply visibility and control. The Refrigerated Carousel provides cold storage and temperature monitoring for medications and is designed to deliver safety, tracking and inventory management.
• Expanded form factors for XR2: Health system pharmacies can now manage more medications through the XR2 Automated Central Pharmacy System, offered through Omnicell’s Central Pharmacy Dispensing Service. Expanded form factor compatibility will further drive safety and visibility for a larger portion of medication inventory.
• Workflow enhancements for XT Anesthesia Workstation: Upgrades to the XT Anesthesia Workstation™ include the addition of a new barcode for syringe labels. Providers can scan medications directly into EHR systems, which should strengthen patient safety measures, helping to deliver the right dose to the right patient. This also enables hospitals to track eligible medications for 340B program compliance.
• New workflow functionality for XT Automated Dispensing Cabinets: New features simplify error resolution for controlled substances, expand partial waste tracking, and enhance telemetry capabilities to maximize system availability.

The Winter 2022 Release supports Omnicell’s commitment to delivering the intelligent infrastructure that supports the journey to the industry-defined vision of the Autonomous Pharmacy.

“Over the last two years, the healthcare industry has faced staffing and supply chain shortages, as well as rising costs, that are fundamentally changing pharmacy care,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “Omnicell is committed to continually innovating and delivering new technologies like IVX Station that are designed to help overcome these challenges, making pharmacy care smarter and safer for all.”

Learn more about Omnicell’s Winter 2022 Release.